Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
Neurocrine (NBIX) Stock Price & Analysis
1,228 Followers
NBIX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$93.28 - $148.37
Previous Close$140.11
Volume728.72K
Average Volume (3M)796.14K
Market Cap
$14.10B
Enterprise Value$13.27B
Total Cash (Recent Filing)$1.21B
Total Debt (Recent Filing)$375.70M
Price to Earnings (P/E)38.5
Beta0.37
Next Earnings
Jul 30, 2024EPS Estimate
$1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.64
Shares Outstanding100,637,227
10 Day Avg. Volume792,947
30 Day Avg. Volume796,138
Standard Deviation0.09
R-Squared0.05
Alpha0.00705
Financial Highlights & Ratios
Price to Book (P/B)6.17
Price to Sales (P/S)7.18
Price to Cash Flow (P/CF)27.40
P/FCF Ratio28.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.69
Enterprise Value/Gross Profit7.18
Enterprise Value/Ebitda26.67
Forecast
1Y Price Target
$164.68Price Target Upside19.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
Neurocrine News
PremiumCompany Announcements
Neurocrine Biosciences Announces CEO Retirement and Succession
Bulls Say, Bears Say
Bulls Say
Clinical DataThe Phase 3 results demonstrate that crinecerfont yields robust androstenedione (A4) control and maintains A4 control while achieving meaningful GC dose reductions.
PartnershipsThe company has established multiple strategic partnerships.
Regulatory ApprovalFDA accepted NBIX’s NDAs for crinecerfont for pediatric and adult patients with CAH and granted Priority Review.
Bears Say
Competitive LandscapeCompetitor CRNX’s atumelnant could emerge as market leader in CAH if early promising data prove durable and can be replicated in larger sample sizes.
Financial PerformanceShares could trade down 10-15% if the '568 Phase 2 study fails to demonstrate compelling results across any of the 4 doses tested.
Regulatory RisksPotential regulatory hurdles could impact the company's drug approvals.
---
Ownership Overview
16.10% Insiders
25.47% Mutual Funds
27.25% Other Institutional Investors
31.18% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $93.28 and its highest was $148.37 in the past 12 months.
What is Neurocrine’s market cap?
Currently, no data Available
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Jul 30, 2024 which is in 27 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on May 01, 2024. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $1.098 by -$0.678.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is $1.16.
How many shares outstanding does Neurocrine have?
Neurocrine has 100,637,230 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $0.42 in its last earnings report, missing expectations of $1.098. Following the earnings report the stock price went up 3.992%.
Which hedge fund is a major shareholder of Neurocrine?
Among the largest hedge funds holding Neurocrine’s share is Dodge & Cox. It holds Neurocrine’s shares valued at 175M.
---
Neurocrine Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$164.68 (19.78% Upside)
$164.68 (19.78% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 457.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.57%
12-Months-Change
Fundamentals
Return on Equity
18.16%
Trailing 12-Months
Asset Growth
47.15%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.
---
NBIX Company Deck
---
NBIX Earnings Call
Q1 2024
0:00 / 0:00
---
NBIX Stock 12 Month Forecast
Average Price Target
$164.68
▲(19.78% Upside)
Technical Analysis
Best Analysts Covering NBIX
1 Year
1 Year Success Rate
22/26 ratings generated profit
1 Year Average Return
+25.52%
reiterated a buy rating 21 days ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +25.52% per trade.
---